Nrx-101
Major Depressive Disorder
NeuroRx, Inc.UNKNOWNPhase 2/3Active
CCC
55/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 81/ 100
Competitive context
197 Active assets in the Major Depressive Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Selegiline Corium Innovations, Inc. | Phase 4 | BBB |
Risperidone Johns Hopkins University | Phase 4 | BBB |
EDIVOXETINE Eli Lilly and Company | Phase 3 | BBB |
Vortioxetine Mayo Clinic | Phase 4 | BBB |
Brexpiprazole Nova Scotia Health Authority | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Nrx-101 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →